deCODE genetics

Inscopix Convenes DECODE Summit to Address the State of Mental Health

Retrieved on:

Wednesday, November 18, 2020

Biotechnology, General Health, Mental health, Medical devices, Health, deCODE genetics, Mental health, Health, Articles

Inscopix, a leading California-based neurotechnology company that empowers breakthroughs in brain science, held the DECODE Summit last week to put a spotlight on the growing mental health crisis.

Key Points:

Inscopix, a leading California-based neurotechnology company that empowers breakthroughs in brain science, held the DECODE Summit last week to put a spotlight on the growing mental health crisis.
View the full release here: https://www.businesswire.com/news/home/20201118005361/en/
Inscopix Convened the DECODE Summit 2020 to Discuss the Mental Health Crisis and the Path Forward.
The DECODE Summit brought together leaders from academia, biopharma industry, philanthropy, advocacy, media, and government to help shape the agenda for the future of mental health.
Kunal Ghosh, CEO & Founder of Inscopix, said about the Summit, Solving the mental health crisis is an All-Hands-On-Deck effort.

FortressIQ Reports Banner Growth Year, Strengthening Mission of Empowering Modern Enterprises to Decode Work

Retrieved on:

Wednesday, November 11, 2020

Business, Articles, deCODE genetics, Lightspeed Venture Partners, M12, Eniac Ventures, Workflow, Economy, Lightspeed

This has been a considerable year of growth for FortressIQ, and were working to constantly uncover new and innovative ways to support our customers throughout their business transformation journeys, said Pankaj Chowdhry, CEO at FortressIQ.

Key Points:

This has been a considerable year of growth for FortressIQ, and were working to constantly uncover new and innovative ways to support our customers throughout their business transformation journeys, said Pankaj Chowdhry, CEO at FortressIQ.
To see FortressIQ in action, request a demo or tune in for a live bi-weekly webinar and Q&A session.
FortressIQ enables enterprises to decode work, transform experiences, and enhance workflows with the industrys most advanced process intelligence platform.
FortressIQ was founded in 2017, and is backed by Lightspeed Venture Partners, Boldstart Ventures, Comcast Ventures, Eniac Ventures, M12 and Tiger Global.

Humoral immune response to SARS-CoV2 in Iceland

Retrieved on:

Tuesday, September 1, 2020

Sarbecovirus, Animal diseases, Health, Zoonoses, Coronavirus disease, Severe acute respiratory syndrome, deCODE genetics, Virus

The aim of the study was to obtain understanding of the nature and durability of the humoral immune response to infection by SARS-CoV-2, the virus that causes COVID-19.

Key Points:

The aim of the study was to obtain understanding of the nature and durability of the humoral immune response to infection by SARS-CoV-2, the virus that causes COVID-19.
They also measured antibodies in4,222 samples from exposed, quarantined persons and 19000 persons not known to have been exposed.
The scientists estimate that 0.9% of Icelanders were infected by SARS-CoV-2 and 44% of people infected with SARS-CoV2 in Iceland were not diagnosed with qPCR.
Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome.

Humoral immune response to SARS-CoV2 in Iceland

Retrieved on:

Tuesday, September 1, 2020

Sarbecovirus, Animal diseases, Health, Zoonoses, Coronavirus disease, Severe acute respiratory syndrome, deCODE genetics, Virus

The aim of the study was to obtain understanding of the nature and durability of the humoral immune response to infection by SARS-CoV-2, the virus that causes COVID-19.

Key Points:

The aim of the study was to obtain understanding of the nature and durability of the humoral immune response to infection by SARS-CoV-2, the virus that causes COVID-19.
They also measured antibodies in4,222 samples from exposed, quarantined persons and 19000 persons not known to have been exposed.
The scientists estimate that 0.9% of Icelanders were infected by SARS-CoV-2 and 44% of people infected with SARS-CoV2 in Iceland were not diagnosed with qPCR.
Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome.

SomaLogic Announces New Agreement with Amgen to Accelerate Drug Discovery and Development Efforts Through Comprehensive Proteomic Profiling

Retrieved on:

Thursday, July 30, 2020

Health, Biotechnology companies, Amgen, deCODE genetics, Clinical trial, Proteomics, Kári Stefánsson

BOULDER, Colo., July 30, 2020 (GLOBE NEWSWIRE) -- SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogics proprietary proteomics technology to help advance Amgens drug discovery and development programs.

Key Points:

BOULDER, Colo., July 30, 2020 (GLOBE NEWSWIRE) -- SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogics proprietary proteomics technology to help advance Amgens drug discovery and development programs.
The agreement builds upon SomaLogics existing collaboration with deCODE genetics , an Amgen subsidiary based in Iceland, and will include broader application across Amgens pipeline.
This new agreement will further enhance these efforts as we seek to enable the discovery of new drug targets and identify the individuals who will respond to specific treatments being developed by Amgen.
Under the terms of the new agreement, SomaLogic will analyze more than 40,000 samples, including samples from Amgen clinical trials.

Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

Retrieved on:

Thursday, April 2, 2020

Medical specialties, Immunology, Medicine, Health, Amgen, Antibody, deCODE genetics, Immune system, Immunity, Adaptive immune system

Amgen will then leverage its world-class antibody engineering and drug development capabilities to select, develop and manufacture antibodies designed to bind and neutralize SARS-CoV-2.

Key Points:

Amgen will then leverage its world-class antibody engineering and drug development capabilities to select, develop and manufacture antibodies designed to bind and neutralize SARS-CoV-2.
deCODE Genetics, a subsidiary of Amgen located in Iceland, will provide genetic insights from patients who were previously infected with COVID-19.
"We are extremely motivated to join forces with our trusted partner, Amgen, to tackle this global health crisis," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

Acclaimed Author and Entrepreneur Alison Cherney Releases New Book, Decode Karma

Retrieved on:

Tuesday, January 21, 2020

Decode Karma , a new book from nationally recognized speaker, writer and business expert Alison Cherney , provides an unprecedented level of research to understand and leverage the mysterious force, including exploration of 160 karmic games.

Key Points:

Decode Karma , a new book from nationally recognized speaker, writer and business expert Alison Cherney , provides an unprecedented level of research to understand and leverage the mysterious force, including exploration of 160 karmic games.
View the full release here: https://www.businesswire.com/news/home/20200121005375/en/
Decode Karma by Alison Cherney now available on Amazon and Barnes & Noble.
Karma is the door to answer the questions that are in the way of peoples success, stated Cherney .
In Decode Karma , Cherney introduces The Karma Checklist , developed through her extensive research to help readers identify which of the 160 karma game(s) they are engaged in with another individual or group of people.

deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

Retrieved on:

Wednesday, September 11, 2019

Branches of biology, Biological databases, Genetics, Biology, Wellcome Trust, UK Biobank, deCODE genetics, Biobank, Whole genome sequencing, Wellcome Sanger Institute, Cathie Sudlow, Kári Stefánsson

REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.

Key Points:

REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.
The project will allow the complete sequencing of the genetic code of all 500,000 participants in the UK Biobank.
The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.
The Whole Genome Sequencing of the UK Biobank participants will be performed by deCODE genetics together with the Wellcome Sanger Institute in the UK with an anticipated completion in the summer of 2021.

deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

Retrieved on:

Wednesday, September 11, 2019

REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.

Key Points:

REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.
The project will allow the complete sequencing of the genetic code of all 500,000 participants in the UK Biobank.
The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.
The Whole Genome Sequencing of the UK Biobank participants will be performed by deCODE genetics together with the Wellcome Sanger Institute in the UK with an anticipated completion in the summer of 2021.

Intermountain Healthcare and deCODE genetics Launch Groundbreaking DNA Study of 500,000 People to Find New Links Between Genetics and Disease

Retrieved on:

Wednesday, June 12, 2019

Health, Genetics, General Health, Biotechnology companies, Biological databases, Health, deCODE genetics, Companies, Intermountain, Amgen, Decoding

Intermountain Healthcare and deCODE genetics have announced a major global collaboration and study focused on discovering new connections between genetics and human disease that will involve the collection of half a million DNA samples.

Key Points:

Intermountain Healthcare and deCODE genetics have announced a major global collaboration and study focused on discovering new connections between genetics and human disease that will involve the collection of half a million DNA samples.
Intermountain Healthcare is a Utah-based not-for-profit integrated healthcare delivery network, and deCODE genetics is a wholly owned subsidiary of Amgen based in Reykjavik, Iceland.
Our partnership with Intermountain Healthcare is important as we continue to identify and validate human disease targets.
These potential discoveries will allow deCODE and Amgen to rapidly develop new medicines that reach the right disease targets.